Monopar Historical Balance Sheet

MNPR Stock

USD 31.55 0.26 0.83%

Trend analysis of Monopar Therapeutics balance sheet accounts such as Net Tangible Assets of 10.9 M provides information on Monopar Therapeutics' total assets, liabilities, and equity, which is the actual value of Monopar Therapeutics to its prevalent stockholders. By breaking down trends over time using Monopar Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Monopar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Monopar Therapeutics is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

About Monopar Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Monopar Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Monopar Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Monopar Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Monopar currently owns. An asset can also be divided into two categories, current and non-current.

Monopar Therapeutics Balance Sheet Chart

At this time, Monopar Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 02/27/2025, Net Invested Capital is likely to grow to about 12.5 M, while Net Tangible Assets are likely to drop slightly above 10.9 M.

Total Assets Total Current Liabilities Total Stockholder Equity Net Tangible Assets

Total Assets

Total assets refers to the total amount of Monopar Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Monopar Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Monopar Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Monopar Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most accounts from Monopar Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 02/27/2025, Net Invested Capital is likely to grow to about 12.5 M, while Net Tangible Assets are likely to drop slightly above 10.9 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	3.1M	1.8M	2.0M	1.1M
Total Assets	13.2M	7.3M	8.4M	11.5M

Total Current Liabilities Total Assets

Monopar Therapeutics balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Total Liab	Total Current Assets	Other Current Liab	Net Debt	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Common Stock Total Equity	Net Invested Capital	Net Working Capital	Common Stock	Capital Stock	Retained Earnings Total Equity	Short Long Term Debt Total	Short Term Debt
Total Assets		0.65	0.99	0.78	-0.69	0.65	0.98	0.65	1.0	0.1	-0.97	-0.76	1.0	0.32	0.83	0.33	0.75	0.66	0.7	0.77	0.47	0.47	0.1	-0.16	-0.16
Total Current Liabilities	0.65		0.54	0.91	-0.89	1.0	0.55	1.0	0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Total Stockholder Equity	0.99	0.54		0.7	-0.6	0.54	0.99	0.54	0.99	0.04	-0.98	-0.7	0.99	0.22	0.76	0.35	0.67	0.57	0.76	0.82	0.37	0.37	0.04	-0.13	-0.13
Net Tangible Assets	0.78	0.91	0.7		-0.93	0.91	0.75	0.91	0.8	0.5	-0.72	-0.85	0.79	0.8	0.98	0.18	0.99	0.93	0.2	0.29	0.88	0.88	0.43	-0.25	-0.25
Retained Earnings	-0.69	-0.89	-0.6	-0.93		-0.89	-0.65	-0.89	-0.71	-0.7	0.58	0.89	-0.72	-0.83	-0.93	-0.24	-0.97	-0.89	-0.08	-0.17	-0.9	-0.9	-0.5	0.48	0.48
Accounts Payable	0.65	1.0	0.54	0.91	-0.89		0.55	1.0	0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Cash	0.98	0.55	0.99	0.75	-0.65	0.55		0.55	0.98	0.14	-0.99	-0.75	0.98	0.32	0.81	0.35	0.73	0.65	0.71	0.77	0.46	0.46	0.13	-0.17	-0.17
Total Liab	0.65	1.0	0.54	0.91	-0.89	1.0	0.55		0.67	0.44	-0.51	-0.77	0.67	0.76	0.86	0.08	0.9	0.86	0.1	0.19	0.83	0.83	0.37	-0.25	-0.25
Total Current Assets	1.0	0.67	0.99	0.8	-0.71	0.67	0.98	0.67		0.12	-0.96	-0.78	1.0	0.34	0.85	0.34	0.77	0.68	0.68	0.75	0.49	0.49	0.11	-0.16	-0.16
Other Current Liab	0.1	0.44	0.04	0.5	-0.7	0.44	0.14	0.44	0.12		0.0	-0.51	0.15	0.82	0.47	-0.02	0.6	0.66	-0.3	-0.24	0.79	0.81	0.79	-0.79	-0.79
Net Debt	-0.97	-0.51	-0.98	-0.72	0.58	-0.51	-0.99	-0.51	-0.96	0.0		0.69	-0.96	-0.23	-0.77	-0.35	-0.68	-0.57	-0.72	-0.78	-0.38	-0.38	0.01	-0.01	-0.01
Non Current Assets Total	-0.76	-0.77	-0.7	-0.85	0.89	-0.77	-0.75	-0.77	-0.78	-0.51	0.69		-0.79	-0.64	-0.91	-0.44	-0.9	-0.81	-0.21	-0.32	-0.74	-0.74	-0.38	0.38	0.38
Cash And Short Term Investments	1.0	0.67	0.99	0.79	-0.72	0.67	0.98	0.67	1.0	0.15	-0.96	-0.79		0.35	0.84	0.32	0.77	0.68	0.69	0.76	0.5	0.5	0.13	-0.2	-0.2
Common Stock Shares Outstanding	0.32	0.76	0.22	0.8	-0.83	0.76	0.32	0.76	0.34	0.82	-0.23	-0.64	0.35		0.72	0.01	0.83	0.89	-0.21	-0.13	0.98	0.98	0.76	-0.5	-0.5
Capital Surpluse	0.83	0.86	0.76	0.98	-0.93	0.86	0.81	0.86	0.85	0.47	-0.77	-0.91	0.84	0.72		0.3	0.98	0.89	0.22	0.32	0.82	0.81	0.4	-0.26	-0.26
Other Current Assets	0.33	0.08	0.35	0.18	-0.24	0.08	0.35	0.08	0.34	-0.02	-0.35	-0.44	0.32	0.01	0.3		0.25	0.0	0.03	0.08	0.0	0.01	-0.02	-0.02	-0.02
Other Stockholder Equity	0.75	0.9	0.67	0.99	-0.97	0.9	0.73	0.9	0.77	0.6	-0.68	-0.9	0.77	0.83	0.98	0.25		0.93	0.14	0.24	0.9	0.9	0.49	-0.36	-0.36
Common Stock Total Equity	0.66	0.86	0.57	0.93	-0.89	0.86	0.65	0.86	0.68	0.66	-0.57	-0.81	0.68	0.89	0.89	0.0	0.93		0.17	0.26	0.95	0.95	0.65	-0.46	-0.46
Net Invested Capital	0.7	0.1	0.76	0.2	-0.08	0.1	0.71	0.1	0.68	-0.3	-0.72	-0.21	0.69	-0.21	0.22	0.03	0.14	0.17		0.99	-0.07	-0.06	-0.2	-0.01	-0.01
Net Working Capital	0.77	0.19	0.82	0.29	-0.17	0.19	0.77	0.19	0.75	-0.24	-0.78	-0.32	0.76	-0.13	0.32	0.08	0.24	0.26	0.99		0.02	0.02	-0.15	-0.05	-0.05
Common Stock	0.47	0.83	0.37	0.88	-0.9	0.83	0.46	0.83	0.49	0.79	-0.38	-0.74	0.5	0.98	0.82	0.0	0.9	0.95	-0.07	0.02		1.0	0.7	-0.48	-0.48
Capital Stock	0.47	0.83	0.37	0.88	-0.9	0.83	0.46	0.83	0.49	0.81	-0.38	-0.74	0.5	0.98	0.81	0.01	0.9	0.95	-0.06	0.02	1.0		0.71	-0.52	-0.52
Retained Earnings Total Equity	0.1	0.37	0.04	0.43	-0.5	0.37	0.13	0.37	0.11	0.79	0.01	-0.38	0.13	0.76	0.4	-0.02	0.49	0.65	-0.2	-0.15	0.7	0.71		-0.8	-0.8
Short Long Term Debt Total	-0.16	-0.25	-0.13	-0.25	0.48	-0.25	-0.17	-0.25	-0.16	-0.79	-0.01	0.38	-0.2	-0.5	-0.26	-0.02	-0.36	-0.46	-0.01	-0.05	-0.48	-0.52	-0.8		1.0
Short Term Debt	-0.16	-0.25	-0.13	-0.25	0.48	-0.25	-0.17	-0.25	-0.16	-0.79	-0.01	0.38	-0.2	-0.5	-0.26	-0.02	-0.36	-0.46	-0.01	-0.05	-0.48	-0.52	-0.8	1.0

Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	16.9M	20.5M	13.2M	7.3M	8.4M	11.5M
Total Current Liabilities	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Total Stockholder Equity	15.7M	18.9M	10.1M	5.6M	6.4M	10.4M
Net Tangible Assets	6.9M	12.6M	15.7M	18.9M	21.8M	10.9M
Retained Earnings	(32.2M)	(41.3M)	(51.8M)	(60.2M)	(54.2M)	(51.5M)
Accounts Payable	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Cash	16.7M	20.3M	8.2M	7.3M	8.4M	10.5M
Total Liab	1.2M	1.6M	3.1M	1.8M	2.0M	1.1M
Total Current Assets	16.8M	20.5M	13.2M	7.3M	8.4M	11.2M
Other Current Liab	1.2M	1.6M	(48.6K)	1.8B	2.0B	2.1B
Net Debt	(16.7M)	(20.3M)	(8.2M)	(7.3M)	(6.5M)	(6.9M)
Cash And Short Term Investments	16.7M	20.3M	13.1M	7.3M	8.4M	12.2M
Common Stock Shares Outstanding	11.0M	12.5M	12.7M	14.5M	16.7M	12.7M
Liabilities And Stockholders Equity	16.9M	20.5M	13.2M	7.3M	8.4M	12.6M
Other Current Assets	62.7K	217.7K	46.0K	66.4K	59.8K	99.5K
Other Stockholder Equity	47.9M	60.2M	61.9M	65.8M	75.7M	46.1M
Net Invested Capital	15.7M	18.9M	10.1M	5.6M	6.4M	12.5M
Net Working Capital	15.6M	18.9M	10.0M	5.6M	6.4M	12.3M
Common Stock	11.5K	12.6K	12.9K	14.9K	17.1K	12.7K
Accumulated Other Comprehensive Income	(7.9K)	(3.2K)	8.9K	(14.1K)	(16.3K)	(15.4K)
Capital Stock	11.5K	12.6K	12.9K	14.9K	17.1K	13.2K

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Monopar Stock

0.65

FENC

Fennec Pharmaceuticals

Pair Corr

Moving against Monopar Stock

0.79	INZY	Inozyme Pharma	Pair Corr
0.79	ABOS	Acumen Pharmaceuticals	Pair Corr
0.67	ILMN	Illumina	Pair Corr
0.47	KURA	Kura Oncology	Pair Corr
0.38	NAMSW	NewAmsterdam Pharma	Pair Corr

The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.

The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Monopar Historical Balance Sheet

About Monopar Balance Sheet Analysis

Monopar Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Net Tangible Assets

Monopar Therapeutics balance sheet Correlations

Monopar Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Monopar Therapeutics balance sheet Accounts

Pair Trading with Monopar Therapeutics

Moving together with Monopar Stock

Moving against Monopar Stock

Additional Tools for Monopar Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Total Current Liabilities
Total Liab	+ 1.0	Accounts Payable
Cash And Short Term Investments	+ 1.0	Total Current Assets

Net Debt	- 0.99	Cash
Net Debt	- 0.98	Total Stockholder Equity
Other Stockholder Equity	- 0.97	Retained Earnings
Net Debt	- 0.97	Total Assets
Cash And Short Term Investments	- 0.96	Net Debt
Net Debt	- 0.96	Total Current Assets